Postmarketing guidance
This article was originally published in The Tan Sheet
Executive Summary
An updated guidance for industry "provides recommendations on procedures, content and format for submitting a postmarketing study status report," FDA announces in the Feb. 16 Federal Register. "Reports on the Status of Postmarketing Study Commitments" also provides "timeframes for FDA's review of postmarketing study commitments; and information about postmarketing study commitments that will be available to the public." The guidance replaces an April 2001 version of the guidance, which was published following the issuance of a final rule on postmarketing study status reports in October 2001 (1"The Tan Sheet" April 16, 2001, p. 6). The overall status of a company's postmarketing commitment is still determined by the study which has made the least progress, according to the guidance...
You may also be interested in...
Postmarketing Study Status To Be Defined By Trial Making Least Progress
The overall status of a company's postmarketing commitment for a product will be determined by the study which has made the least progress, according to an FDA draft guidance.
Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
Amneal’s Generics Business Reinvigorated By New Launches
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: